TOX and primary cutaneous T-cell non-Hodgkin lymphoma: Recent studies showed aberrant expression of TOX in different types of CTCL, mainly Sézary syndrome (SS) and mycosis fungoides (MF), but also in primary cutaneous CD30+ lymphoproliferative disorders, including primary cutaneous anaplastic large cell lymphoma and lymphomatoid papulosis (LyP), though with lower intensity, and cases of adult T-cell leukemia/lymphoma and peripheral T-cell lymphoma, not otherwise specified [4, 7, 8, 15].